Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Effects of insulin resistance on skeletal muscle growth and exercise capacity in type 2 diabetic mouse models.

Ostler JE, Maurya SK, Dials J, Roof SR, Devor ST, Ziolo MT, Periasamy M.

Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E592-605. doi: 10.1152/ajpendo.00277.2013. Epub 2014 Jan 14.

2.

1-Deoxynojirimycin Alleviates Insulin Resistance via Activation of Insulin Signaling PI3K/AKT Pathway in Skeletal Muscle of db/db Mice.

Liu Q, Li X, Li C, Zheng Y, Peng G.

Molecules. 2015 Dec 4;20(12):21700-14. doi: 10.3390/molecules201219794.

3.

Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.

Wang X, Hu Z, Hu J, Du J, Mitch WE.

Endocrinology. 2006 Sep;147(9):4160-8. Epub 2006 Jun 15.

PMID:
16777975
4.

Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.

Schrauwen P, Mensink M, Schaart G, Moonen-Kornips E, Sels JP, Blaak EE, Russell AP, Hesselink MK.

J Clin Endocrinol Metab. 2006 Apr;91(4):1520-5. Epub 2005 Dec 29.

PMID:
16384852
5.

Exercise adds to metformin and acarbose efficacy in db/db mice.

Tang T, Reed MJ.

Metabolism. 2001 Sep;50(9):1049-53.

PMID:
11555837
6.

Anti-hyperglycemic and hypolipidemic effects of Cistanche tubulosa in type 2 diabetic db/db mice.

Xiong WT, Gu L, Wang C, Sun HX, Liu X.

J Ethnopharmacol. 2013 Dec 12;150(3):935-45. doi: 10.1016/j.jep.2013.09.027. Epub 2013 Oct 1.

PMID:
24095831
7.

MicroRNA-194 Modulates Glucose Metabolism and Its Skeletal Muscle Expression Is Reduced in Diabetes.

Latouche C, Natoli A, Reddy-Luthmoodoo M, Heywood SE, Armitage JA, Kingwell BA.

PLoS One. 2016 May 10;11(5):e0155108. doi: 10.1371/journal.pone.0155108. eCollection 2016.

8.

Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.

Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M.

Hypertension. 2004 May;43(5):1003-10. Epub 2004 Mar 22.

10.

Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice.

Takada S, Hirabayashi K, Kinugawa S, Yokota T, Matsushima S, Suga T, Kadoguchi T, Fukushima A, Homma T, Mizushima W, Masaki Y, Furihata T, Katsuyama R, Okita K, Tsutsui H.

Eur J Pharmacol. 2014 Oct 5;740:690-6. doi: 10.1016/j.ejphar.2014.06.008. Epub 2014 Jun 22.

PMID:
24964389
11.

Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice.

Wang CD, Teng BS, He YM, Wu JS, Pan D, Pan LF, Zhang D, Fan ZH, Yang HJ, Zhou P.

Br J Nutr. 2012 Dec 14;108(11):2014-25. doi: 10.1017/S0007114512000153. Epub 2012 Mar 27.

PMID:
22453054
12.

Unacylated ghrelin restores insulin and autophagic signaling in skeletal muscle of diabetic mice.

Tam BT, Pei XM, Yung BY, Yip SP, Chan LW, Wong CS, Siu PM.

Pflugers Arch. 2015 Dec;467(12):2555-69. doi: 10.1007/s00424-015-1721-5. Epub 2015 Jul 31.

PMID:
26228926
13.

Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.

Trasino SE, Tang XH, Jessurun J, Gudas LJ.

Diabetes Obes Metab. 2016 Feb;18(2):142-51. doi: 10.1111/dom.12590. Epub 2015 Dec 23.

14.

Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.

Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, Song HK, Nam DH, Han JY, Han SY, Han KH, Kang YS, Cha DR.

Endocrinology. 2013 Sep;154(9):3366-76. doi: 10.1210/en.2012-2276. Epub 2013 Jul 3.

PMID:
23825123
15.

Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in skeletal muscle.

Liu M, Wu K, Mao X, Wu Y, Ouyang J.

J Ethnopharmacol. 2010 Jan 8;127(1):32-7. doi: 10.1016/j.jep.2009.09.055. Epub 2009 Oct 2.

PMID:
19800959
16.

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC.

Metabolism. 2013 Nov;62(11):1623-32. doi: 10.1016/j.metabol.2013.06.008. Epub 2013 Aug 15.

PMID:
23953944
17.

Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver.

Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S.

Diabetes. 2013 Mar;62(3):811-24. doi: 10.2337/db11-1652. Epub 2012 Dec 3.

18.

Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency.

Hu J, Klein JD, Du J, Wang XH.

Endocrinology. 2008 Nov;149(11):5384-90. doi: 10.1210/en.2008-0132. Epub 2008 Jul 24.

19.

Early or advanced stage type 2 diabetes is not accompanied by in vivo skeletal muscle mitochondrial dysfunction.

De Feyter HM, van den Broek NM, Praet SF, Nicolay K, van Loon LJ, Prompers JJ.

Eur J Endocrinol. 2008 May;158(5):643-53. doi: 10.1530/EJE-07-0756.

20.

Antidiabetic, antihyperlipidemic and antioxidant activities of a novel proteoglycan from ganoderma lucidum fruiting bodies on db/db mice and the possible mechanism.

Pan D, Zhang D, Wu J, Chen C, Xu Z, Yang H, Zhou P.

PLoS One. 2013 Jul 11;8(7):e68332. doi: 10.1371/journal.pone.0068332. Print 2013.

Supplemental Content

Support Center